What is Abbvie Inc's earnings per share (EPS)?

Abbvie Inc (ABBV) reported diluted earnings per share of $2.36 for fiscal year 2025. This represents a -1.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Abbvie Inc Financials

ABBV

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Abbvie Inc (ABBV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 58/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Abbvie Inc has an operating margin of 24.6%, meaning the company retains $25 of operating profit per $100 of revenue. This strong profitability earns a score of 77/100, reflecting efficient cost management and pricing power. This is up from 16.2% the prior year.

Growth

Abbvie Inc's revenue grew 8.6% year-over-year to $61.2B, a solid pace of expansion. This earns a growth score of 48/100.

Liquidity

Abbvie Inc's current ratio of 0.67 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 8/100, which could limit financial flexibility.

Cash Flow

Abbvie Inc converts 29.1% of revenue into free cash flow ($17.8B). This strong cash generation earns a score of 98/100.

Altman Z-Score Grey Zone

2.22

Abbvie Inc scores 2.22, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($384.7B) relative to total liabilities ($137.2B). This signals moderate financial risk that warrants monitoring.

Piotroski F-Score Strong

7/9

Abbvie Inc passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

4.50x

For every $1 of reported earnings, Abbvie Inc generates $4.50 in operating cash flow ($19.0B OCF vs $4.2B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

5.2x

Abbvie Inc earns $5.2 in operating income for every $1 of interest expense ($15.1B vs $2.9B). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$61.2B

YoY+8.6%

5Y CAGR+6.0%

10Y CAGR+10.3%

Abbvie Inc generated $61.2B in revenue in fiscal year 2025. This represents an increase of 8.6% from the prior year.

EBITDA

$23.2B

YoY+32.5%

5Y CAGR+5.4%

10Y CAGR+10.7%

Abbvie Inc's EBITDA was $23.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 32.5% from the prior year.

Net Income

$4.2B

YoY-1.2%

5Y CAGR-1.7%

10Y CAGR-1.9%

Abbvie Inc reported $4.2B in net income in fiscal year 2025. This represents a decrease of 1.2% from the prior year.

EPS (Diluted)

$2.36

YoY-1.3%

5Y CAGR-2.8%

10Y CAGR-2.8%

Abbvie Inc earned $2.36 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 1.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$17.8B

YoY-0.1%

5Y CAGR+1.2%

10Y CAGR+9.8%

Abbvie Inc generated $17.8B in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 0.1% from the prior year.

Cash & Debt

$5.2B

YoY-5.3%

5Y CAGR-9.2%

10Y CAGR-4.6%

Abbvie Inc held $5.2B in cash against $64.5B in long-term debt as of fiscal year 2025.

Dividends Per Share

$6.65

YoY+5.7%

5Y CAGR+6.6%

10Y CAGR+12.2%

Abbvie Inc paid $6.65 per share in dividends in fiscal year 2025. This represents an increase of 5.7% from the prior year.

Shares Outstanding

1.77B

YoY+0.2%

5Y CAGR+0.0%

10Y CAGR+0.9%

Abbvie Inc had 1.77B shares outstanding in fiscal year 2025. This represents an increase of 0.2% from the prior year.

Margins & Returns

Gross Margin

70.2%

YoY+0.3pp

5Y CAGR+3.8pp

10Y CAGR-10.1pp

Abbvie Inc's gross margin was 70.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.3 percentage points from the prior year.

Operating Margin

24.6%

YoY+8.4pp

5Y CAGR-0.2pp

10Y CAGR-8.3pp

Abbvie Inc's operating margin was 24.6% in fiscal year 2025, reflecting core business profitability. This is up 8.4 percentage points from the prior year.

Net Margin

6.9%

YoY-0.7pp

5Y CAGR-3.2pp

10Y CAGR-15.6pp

Abbvie Inc's net profit margin was 6.9% in fiscal year 2025, showing the share of revenue converted to profit. This is down 0.7 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$9.1B

YoY-28.9%

5Y CAGR+7.4%

10Y CAGR+7.8%

Abbvie Inc invested $9.1B in research and development in fiscal year 2025. This represents a decrease of 28.9% from the prior year.

Share Buybacks

$980.0M

YoY-42.6%

5Y CAGR+0.0%

10Y CAGR-18.5%

Abbvie Inc spent $980.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 42.6% from the prior year.

Capital Expenditures

$1.2B

YoY+24.6%

5Y CAGR+8.8%

10Y CAGR+8.6%

Abbvie Inc invested $1.2B in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 24.6% from the prior year.

ABBV Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$61.2B+8.6%	$56.3B+3.7%	$54.3B-6.4%	$58.1B+3.3%	$56.2B+22.7%	$45.8B
Cost of Revenue	$18.2B+7.7%	$16.9B-17.2%	$20.4B+17.2%	$17.4B-0.2%	$17.4B+13.4%	$15.4B
Gross Profit	$43.0B+8.9%	$39.4B+16.3%	$33.9B-16.6%	$40.6B+4.9%	$38.8B+27.4%	$30.4B
R&D Expenses	$9.1B-28.9%	$12.8B+66.7%	$7.7B+17.9%	$6.5B-6.0%	$6.9B+8.5%	$6.4B
SG&A Expenses	$14.0B-5.0%	$14.8B+14.6%	$12.9B-15.6%	$15.3B+23.6%	$12.3B+9.3%	$11.3B
Operating Income	$15.1B+65.0%	$9.1B-28.4%	$12.8B-29.6%	$18.1B+1.1%	$17.9B+57.7%	$11.4B
Interest Expense	$2.9B+3.0%	$2.8B+26.3%	$2.2B-0.3%	$2.2B-8.0%	$2.4B-1.3%	$2.5B
Income Tax	$2.4B+514.7%	-$570.0M-141.4%	$1.4B-15.6%	$1.6B+13.3%	$1.4B+217.6%	-$1.2B
Net Income	$4.2B-1.2%	$4.3B-12.0%	$4.9B-58.9%	$11.8B+2.5%	$11.5B+150.0%	$4.6B
EPS (Diluted)	$2.36-1.3%	$2.39-12.1%	$2.72-59.0%	$6.63+2.8%	$6.45+137.1%	$2.72

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$16.6B+5.3%	$15.8B+2.3%	$15.4B+15.6%	$13.3B-11.6%	$15.1B+4.4%	$14.5B0.0%	$14.5B+17.5%	$12.3B
Cost of Revenue	N/A	$5.3B+22.0%	$4.3B+8.6%	$4.0B	N/A	$4.2B+0.2%	$4.2B+2.6%	$4.1B
Gross Profit	$12.1B+15.2%	$10.5B-5.5%	$11.1B+18.6%	$9.3B-12.7%	$10.7B+4.5%	$10.2B-0.1%	$10.3B+24.9%	$8.2B
R&D Expenses	N/A	$2.3B+8.8%	$2.1B+3.1%	$2.1B	N/A	$2.1B+9.3%	$1.9B+0.5%	$1.9B
SG&A Expenses	N/A	$3.6B+9.7%	$3.3B-1.2%	$3.3B	N/A	$4.2B+24.5%	$3.4B+1.9%	$3.3B
Operating Income	N/A	$1.9B-61.1%	$4.9B+31.1%	$3.7B	N/A	$3.8B-4.2%	$4.0B+42.9%	$2.8B
Interest Expense	N/A	$739.0M-0.1%	$740.0M+5.7%	$700.0M	N/A	$720.0M-0.8%	$726.0M+10.0%	$660.0M
Income Tax	N/A	$526.0M-14.2%	$613.0M+64.8%	$372.0M	N/A	$520.0M-32.7%	$773.0M+101.8%	$383.0M
Net Income	$1.8B+876.3%	$186.0M-80.2%	$938.0M-27.1%	$1.3B+5945.5%	-$22.0M-101.4%	$1.6B+13.9%	$1.4B+0.1%	$1.4B
EPS (Diluted)	$1.02+920.0%	$0.10-80.8%	$0.52-27.8%	$0.72+3700.0%	$-0.02-102.3%	$0.88+14.3%	$0.770.0%	$0.77

ABBV Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$134.0B-0.9%	$135.2B+0.3%	$134.7B-2.9%	$138.8B-5.3%	$146.5B-2.7%	$150.6B
Current Assets	$29.1B+13.6%	$25.6B-22.5%	$33.0B+15.9%	$28.5B+1.9%	$27.9B+15.5%	$24.2B
Cash & Equivalents	$5.2B-5.3%	$5.5B-56.9%	$12.8B+39.3%	$9.2B-5.6%	$9.7B+15.4%	$8.4B
Inventory	$5.0B+18.4%	$4.2B+2.0%	$4.1B+14.5%	$3.6B+14.4%	$3.1B-5.5%	$3.3B
Accounts Receivable	$12.6B+15.3%	$10.9B-2.1%	$11.2B-0.9%	$11.3B+12.8%	$10.0B+13.1%	$8.8B
Goodwill	$35.6B+2.0%	$35.0B+8.2%	$32.3B+0.4%	$32.2B-0.7%	$32.4B-2.2%	$33.1B
Total Liabilities	$137.2B+4.1%	$131.8B+6.0%	$124.4B+2.3%	$121.6B-7.3%	$131.1B-4.6%	$137.5B
Current Liabilities	$43.3B+11.7%	$38.7B+2.4%	$37.8B+28.1%	$29.5B-16.1%	$35.2B+22.8%	$28.7B
Long-Term Debt	$64.5B-3.5%	$66.8B+12.8%	$59.2B-6.2%	$63.1B-16.9%	$76.0B-10.6%	$84.9B
Total Equity	-$3.3B-198.3%	$3.3B-67.9%	$10.4B-40.0%	$17.3B+12.0%	$15.4B+17.8%	$13.1B
Retained Earnings	-$15.5B-96.1%	-$7.9B-690.0%	-$1.0B-120.9%	$4.8B+53.0%	$3.1B+196.4%	$1.1B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$134.0B0.0%	$133.9B-2.4%	$137.2B+0.7%	$136.2B+0.7%	$135.2B-5.8%	$143.4B+1.0%	$141.9B-4.7%	$148.9B
Current Assets	$29.1B+1.8%	$28.5B-2.5%	$29.3B+5.7%	$27.7B+8.2%	$25.6B-7.9%	$27.8B-17.8%	$33.8B-13.0%	$38.9B
Cash & Equivalents	$5.2B-7.1%	$5.6B-13.0%	$6.5B+25.0%	$5.2B-6.3%	$5.5B-23.9%	$7.3B-44.7%	$13.1B-27.3%	$18.1B
Inventory	$5.0B+0.3%	$4.9B-0.4%	$5.0B+9.6%	$4.5B+8.3%	$4.2B-6.0%	$4.5B+5.5%	$4.2B-0.6%	$4.2B
Accounts Receivable	$12.6B-1.4%	$12.8B+1.0%	$12.6B+1.3%	$12.5B+14.3%	$10.9B-4.8%	$11.5B-2.1%	$11.7B-1.9%	$11.9B
Goodwill	$35.6B0.0%	$35.6B0.0%	$35.6B+1.0%	$35.3B+0.9%	$35.0B-1.0%	$35.3B+5.7%	$33.4B-0.1%	$33.4B
Total Liabilities	$137.2B+0.5%	$136.5B-0.6%	$137.4B+1.9%	$134.7B+2.2%	$131.8B-4.0%	$137.4B+1.7%	$135.2B-4.1%	$140.9B
Current Liabilities	$43.3B+9.9%	$39.4B-0.9%	$39.8B+9.2%	$36.4B-6.1%	$38.7B-10.0%	$43.1B+2.7%	$41.9B+0.9%	$41.5B
Long-Term Debt	$64.5B+2.4%	$63.0B0.0%	$63.0B-2.4%	$64.5B-3.5%	$66.8B+14.2%	$58.5B+0.8%	$58.0B-9.0%	$63.8B
Total Equity	-$3.3B-23.8%	-$2.6B-1343.7%	-$183.0M-112.9%	$1.4B-57.3%	$3.3B-44.9%	$6.0B-11.0%	$6.8B-15.3%	$8.0B
Retained Earnings	-$15.5B-8.8%	-$14.2B-23.7%	-$11.5B-20.7%	-$9.5B-20.6%	-$7.9B-59.1%	-$5.0B-31.7%	-$3.8B-58.1%	-$2.4B

ABBV Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$19.0B+1.2%	$18.8B-17.7%	$22.8B-8.4%	$24.9B+9.5%	$22.8B+29.5%	$17.6B
Capital Expenditures	$1.2B+24.6%	$974.0M+25.4%	$777.0M+11.8%	$695.0M-11.7%	$787.0M-1.4%	$798.0M
Free Cash Flow	$17.8B-0.1%	$17.8B-19.2%	$22.1B-9.0%	$24.2B+10.3%	$22.0B+31.0%	$16.8B
Investing Cash Flow	-$6.6B+68.1%	-$20.8B-936.3%	-$2.0B-222.5%	-$623.0M+73.4%	-$2.3B+93.8%	-$37.6B
Financing Cash Flow	-$12.7B-144.2%	-$5.2B+69.7%	-$17.2B+30.6%	-$24.8B-30.3%	-$19.0B-65.5%	-$11.5B
Dividends Paid	$11.7B+5.7%	$11.0B+4.6%	$10.5B+4.9%	$10.0B+8.4%	$9.3B+20.0%	$7.7B
Share Buybacks	$980.0M-42.6%	$1.7B-13.4%	$2.0B+32.6%	$1.5B+59.2%	$934.0M-4.5%	$978.0M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$5.2B-25.7%	$7.0B+36.3%	$5.2B+215.2%	$1.6B-76.8%	$7.0B+29.4%	$5.4B+139.9%	$2.3B-43.8%	$4.0B
Capital Expenditures	$329.0M-13.6%	$381.0M+41.6%	$269.0M+14.5%	$235.0M-19.2%	$291.0M+16.9%	$249.0M+3.3%	$241.0M+24.9%	$193.0M
Free Cash Flow	$4.9B-26.4%	$6.6B+36.0%	$4.9B+248.9%	$1.4B-79.3%	$6.8B+30.0%	$5.2B+156.1%	$2.0B-47.2%	$3.8B
Investing Cash Flow	-$1.5B+55.2%	-$3.3B-176.4%	-$1.2B-60.7%	-$735.0M+60.8%	-$1.9B+77.3%	-$8.3B-649.2%	-$1.1B+88.5%	-$9.6B
Financing Cash Flow	-$4.2B+9.2%	-$4.6B-69.4%	-$2.7B-115.4%	-$1.3B+81.7%	-$6.9B-123.3%	-$3.1B+49.6%	-$6.1B-156.4%	$10.8B
Dividends Paid	$2.9B0.0%	$2.9B0.0%	$2.9B-0.5%	$2.9B+6.3%	$2.8B0.0%	$2.8B0.0%	$2.8B-0.8%	$2.8B
Share Buybacks	$3.0M-25.0%	$4.0M-66.7%	$12.0M-98.8%	$961.0M+168.4%	$358.0M+2005.9%	$17.0M+88.9%	$9.0M-99.3%	$1.3B

ABBV Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	70.2%+0.3pp	70.0%+7.6pp	62.4%-7.6pp	70.0%+1.0pp	69.0%+2.5pp	66.4%
Operating Margin	24.6%+8.4pp	16.2%-7.3pp	23.5%-7.7pp	31.2%-0.7pp	31.9%+7.1pp	24.8%
Net Margin	6.9%-0.7pp	7.6%-1.4pp	8.9%-11.4pp	20.4%-0.2pp	20.5%+10.5pp	10.1%
Return on Equity	N/A	128.7%+81.7pp	46.9%-21.7pp	68.6%-6.3pp	74.9%+39.6pp	35.3%
Return on Assets	3.1%-0.0pp	3.2%-0.4pp	3.6%-4.9pp	8.5%+0.7pp	7.9%+4.8pp	3.1%
Current Ratio	0.67+0.0	0.66-0.2	0.87-0.1	0.96+0.2	0.79-0.0	0.84
Debt-to-Equity	-19.73-39.8	20.10+14.4	5.72+2.1	3.66-1.3	4.93-1.6	6.50
FCF Margin	29.1%-2.5pp	31.6%-9.0pp	40.6%-1.2pp	41.8%+2.6pp	39.1%+2.5pp	36.7%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	72.6%+6.2pp	66.4%-5.4pp	71.8%+1.8pp	70.0%-0.9pp	70.9%+0.0pp	70.9%-0.1pp	70.9%+4.2pp	66.7%
Operating Margin	N/A	12.1%-19.7pp	31.7%+3.8pp	28.0%	N/A	26.5%-1.1pp	27.6%+4.9pp	22.7%
Net Margin	10.9%+9.7pp	1.2%-4.9pp	6.1%-3.6pp	9.6%+9.8pp	-0.1%-10.9pp	10.8%+1.3pp	9.5%-1.6pp	11.1%
Return on Equity	N/A	N/A	N/A	90.6%+91.2pp	-0.7%-26.5pp	25.9%+5.7pp	20.2%+3.1pp	17.1%
Return on Assets	1.4%+1.2pp	0.1%-0.5pp	0.7%-0.3pp	0.9%+1.0pp	-0.0%-1.1pp	1.1%+0.1pp	1.0%+0.1pp	0.9%
Current Ratio	0.67-0.1	0.72-0.0	0.74-0.0	0.76+0.1	0.66+0.0	0.65-0.2	0.81-0.1	0.94
Debt-to-Equity	-19.73+4.1	-23.83+320.2	-344.04-389.5	45.44+25.3	20.10+10.4	9.70+1.1	8.56+0.6	7.97
FCF Margin	29.4%-12.7pp	42.1%+10.4pp	31.7%+21.2pp	10.5%-34.3pp	44.7%+8.8pp	35.9%+21.9pp	14.0%-17.2pp	31.3%

Note: Shareholder equity is negative (-$3.3B), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.67), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Johnson & Johnson JNJ

$588.8B

$305.9B

$291.5B

$821.7B

$163.2B

Frequently Asked Questions

What is Abbvie Inc's annual revenue?

Abbvie Inc (ABBV) reported $61.2B in total revenue for fiscal year 2025. This represents a 8.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Abbvie Inc's revenue growing?

Abbvie Inc (ABBV) revenue grew by 8.6% year-over-year, from $56.3B to $61.2B in fiscal year 2025.

Is Abbvie Inc profitable?

Yes, Abbvie Inc (ABBV) reported a net income of $4.2B in fiscal year 2025, with a net profit margin of 6.9%.

What is Abbvie Inc's EBITDA?

Abbvie Inc (ABBV) had EBITDA of $23.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Abbvie Inc have?

As of fiscal year 2025, Abbvie Inc (ABBV) had $5.2B in cash and equivalents against $64.5B in long-term debt.

What is Abbvie Inc's gross margin?

Abbvie Inc (ABBV) had a gross margin of 70.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Abbvie Inc's operating margin?

Abbvie Inc (ABBV) had an operating margin of 24.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Abbvie Inc's net profit margin?

Abbvie Inc (ABBV) had a net profit margin of 6.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Abbvie Inc pay dividends?

Yes, Abbvie Inc (ABBV) paid $6.65 per share in dividends during fiscal year 2025.

What is Abbvie Inc's free cash flow?

Abbvie Inc (ABBV) generated $17.8B in free cash flow during fiscal year 2025. This represents a -0.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Abbvie Inc's operating cash flow?

Abbvie Inc (ABBV) generated $19.0B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Abbvie Inc's total assets?

Abbvie Inc (ABBV) had $134.0B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Abbvie Inc's capital expenditures?

Abbvie Inc (ABBV) invested $1.2B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Abbvie Inc spend on research and development?

Abbvie Inc (ABBV) invested $9.1B in research and development during fiscal year 2025.

Does Abbvie Inc buy back shares?

Yes, Abbvie Inc (ABBV) spent $980.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Abbvie Inc have outstanding?

Abbvie Inc (ABBV) had 1.77B shares outstanding as of fiscal year 2025.

What is Abbvie Inc's current ratio?

Abbvie Inc (ABBV) had a current ratio of 0.67 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Abbvie Inc's debt-to-equity ratio?

Abbvie Inc (ABBV) had a debt-to-equity ratio of -19.73 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Abbvie Inc's return on assets (ROA)?

Abbvie Inc (ABBV) had a return on assets of 3.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Why is Abbvie Inc's debt-to-equity ratio negative or unusual?

Abbvie Inc (ABBV) has negative shareholder equity of -$3.3B as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Abbvie Inc's Altman Z-Score?

Abbvie Inc (ABBV) has an Altman Z-Score of 2.22, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Abbvie Inc's Piotroski F-Score?

Abbvie Inc (ABBV) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Abbvie Inc's earnings high quality?

Abbvie Inc (ABBV) has an earnings quality ratio of 4.50x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Abbvie Inc cover its interest payments?

Abbvie Inc (ABBV) has an interest coverage ratio of 5.2x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Abbvie Inc?

Abbvie Inc (ABBV) scores 58 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.